Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

Fortier hopes the discovery that this pathway reverses fibrosis leads to exploration of additional brakes on fibrosis. "So much work on fibrosis has focused on how we can prevent it, but when a ...

There are few effective treatments for intestinal fibrosis because researchers have ... disrupts the macrophages and activates the HIF-1α pathway. Pro-fibrotic genes are then expressed in both ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it. And, as University of South Florida pulmonologist Dr. Jose ...

New York, USA, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...

Now, however, the challenge is to prove that fibrosis can be reversed by a direct attack on the pathways of fibrogenesis and matrix degradation, instead of therapy directed only to the primary ...

Most ICBs in England do not have effective referral pathways for diagnosing and managing liver disease, an analysis has shown ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced its second FDA authorization, securing 510(k) cl ...

The transcription factor sex-determining region Y-related high-mobility group-box gene 9 (SOX9) plays a critical role in ...